Rajyalakshmi Mulukutla, MD
Ophthalmology · Middletown, CTNPI 1659382034
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,689 of the $6,081 with a category attached, or 77.1%. 27 manufacturers reported payments, led by Alcon at 43.6% of the total.
Across 165 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Bausch & Lomb Americas Inc.$617
- AbbVie$482
- Sun Pharmaceutical Industries Inc.$391
- Glaukos Corporation$385
- Kala Pharmaceuticals, Inc.$213
- plus $1K from 21 others
What the payments were for
- Travel & lodging$87814%
- Food & beverage$4,68977%
- Gifts$451%
- Other$4688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $2,652 |
| Bausch & Lomb Americas Inc. | 18 | $617 |
| AbbVie(2 entities) | 27 | $482 |
| Sun Pharmaceutical Industries Inc. | 11 | $391 |
| Glaukos Corporation | 5 | $385 |
| Kala Pharmaceuticals, Inc. | 11 | $213 |
| Oyster Point Pharma, Inc. | 10 | $181 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $148 |
| Novartis | 7 | $139 |
| Ocular Therapeutix, Inc. | 1 | $121 |
| Tarsus Pharmaceuticals, Inc. | 6 | $107 |
| Apellis Pharmaceuticals, Inc. | 1 | $103 |
| Harrow Eye, LLC | 3 | $79 |
| Rayner Intraocular Lenses Limited | 3 | $60 |
| Shire North American Group Inc | 3 | $57 |
| Thea Pharma Inc. | 3 | $56 |
| Aerie Pharmaceuticals, Inc. | 3 | $50 |
| Nova Eye, Inc. | 1 | $43 |
| Sight Sciences, Inc. | 2 | $33 |
| Dompe US, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $23 |
| Rxsight Inc | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Ivantis, Inc | 1 | $20 |
| Omeros Corporation | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| NEW World Medical,inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Unity$468
- IC-8 Apthera IOL$251
- Clareon PanOptix Pro$122
- DEXTENZA$121
- CEQUA$112
- iDose$102
How this compares
$6,081 in reported general payments places this provider in the 85th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $100,247 |
| Cyclosporine | 66 | $39,357 |
| XiidraLifitegrast | 13 | $19,958 |
| LumiganBimatoprost | 37 | $17,663 |
| VyzultaLatanoprostene Bunod | 14 | $10,430 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,100 |
| ZirganGanciclovir | 12 | $5,689 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $5,333 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,527 |
| Doxycycline Hyclate | 15 | $3,837 |
| ValacyclovirValacyclovir Hcl | 32 | $3,476 |
| Travoprost | 25 | $3,363 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,893 |
| Latanoprost | 145 | $2,029 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 44 | $1,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $482 | $122,437141 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo, Zirgan | $617 | $45,17751 claims |
| AlconSimbrinza | $2,652 | $2,89314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Middletown
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
- Madina FalconeFarmington$23K
- Flora LevinBridgeport$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.